Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of HIP2105 vs RLD2104 in Healthy Volunteers
NCT04975711Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Nov 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esomeprazole and Magnesium hydroxide in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area under the concentration-time curve over the dosing interval and Changed rate from baseline in 24h integrated gastric pH. Started Jul 2021; status: completed.
02
Drugs
esomeprazoleMagnesium hydroxide
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04975711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975711.